LUND, Sweden, Sept. 3, 2021 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") announces today that board member Martin Møller
purchases 1,056 shares in Immunovia, an investment of a total of
SEK 141,295. This is Martin Møller's
total holding after the purchase.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please
This information was brought to you by Cision
The following files are available for download: